Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda Picks Up Late-Stage Parkinson's Candidate With $363m Biotie Buy

This article was originally published in Scrip

Executive Summary

Acorda Therapeutics Inc.'s president and CEO Ron Cohen has been dropping hints for some months that he was pursuing significant business development opportunities and the EU was his preferred hunting ground. Finally, on Jan. 19, Acorda said it has agreed to acquire Biotie Therapies Corp. of Finland for around $363m. Biotie has a Parkinson's disease drug candidate in Phase III which has a mechanism of action that has caused problems for other companies.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts